During Monday’s current trade, Arrowhead Research Corp. (NASDAQ:ARWR)’s shares gained 4.03% to $8.23, after a biopharmaceutical company declared that the United States Food and Drug Administration (FDA) informed the Company that it can proceed with a multiple-dose Phase 2b clinical study of ARC-520, its clinical candidate for the treatment of chronic hepatitis B infection, under an investigational new drug (IND) application formerly filed with the FDA.
The clinical study, titled Heparc-2004, is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study of ARC-520 administered intravenously to patients with chronic immune active HBV infection maintained on entecavir or tenofovir therapy. The study is planned to enroll up to 12 patients who will be randomized at a ratio of 2:1 with 8 patients receiving 1 mg/kg of ARC-520 and 4 patients receiving placebo. Each patient will receive 3 total doses, once every 4 weeks. Patients will be followed through Day 147.
The primary objective of Heparc-2004 is to evaluate the depth of hepatitis B surface antigen (HBsAg) decline in response to multiple doses of ARC-520 contrast to placebo in patients with chronic, immune active HBV infection as a measure of drug activity. Secondary objectives are to measure safety and tolerability and pharmacokinetics of ARC-520, and to evaluate the effect of ARC-520 on entecavir or tenofovir pharmacokinetics, in addition to other exploratory safety and pharmacodynamic objectives.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
During an afternoon trade, Alibaba Group Holding Limited (NYSE:BABA)’s shares declined -0.50% to $84.15, as DTS, Inc. (DTSI), a global leader in high-definition audio solutions, has integrated its DTS-HD sound technology in the Tmall Box, the set-top box operated by the digital entertainment unit of Alibaba Group (NYSE: BABA). Powered by the Amlogic quad-core System-on-Chip (SoC), this partnership provides Chinese consumers with a high-quality home entertainment experience for streaming content and connected devices.
The Tmall Box offers pay TV, online video streaming, music, video games and other digital entertainment options, and is now available on Tmall.com, China’s largest B2C shopping platform operated by Alibaba Group.
DTS-HD features next-generation decoding technology that enables equipped products to process more advanced audio, such as broader support for low-bit-rate (LBR) streaming media and adaptive streaming to overcome bandwidth, storage and network constraints.
Alibaba Group Holding Limited, through its subsidiaries, operates as an online and mobile commerce company in the People’s Republic of China and internationally. It operates Taobao Marketplace, an online shopping destination; Tmall, a third-party platform for brands and retailers; Juhuasuan, a group buying marketplace; Alibaba.com, an online business-to-business marketplace that focuses on global trade among businesses; 1688.com, an online wholesale marketplace; and AliExpress, a consumer marketplace.
ARCA biopharma, Inc. (NASDAQ:ABIO), during its Monday’s current trading session gained 25.01%, to $1.05, after ARCA declared that the FDA has designated as a Fast Track development program the investigation of Gencaro for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population (heart failure patients with reduced left ventricular ejection fraction, HFREF).
- Gencaro is the company’s investigational, pharmacologically unique beta-blocker and mild vasodilator.
- Gencaro is presently being evaluated as a potential treatment for atrial fibrillation in a genetically-defined heart failure population in GENETIC-AF, a Phase 2B/3 adaptive design clinical trial.
- ARCA anticipates that enrollment of about 200 patients in the Phase 2B portion of the trial will be accomplished by the end of 2016.
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Finally, KeyCorp. (NYSE:KEY), gained 0.89% Monday, as on April 7, Acuity Brands, Inc. (AYI) and Key Equipment Finance declared that the two companies have teamed up to provide flexible financing solutions to qualified Acuity Brands customers converting to energy-efficient LED lighting and installing smart lighting networks. Key Equipment Finance is one of the largest bank-held equipment finance companies in the U.S. and an associate of KeyCorp (KEY).
The arrangement will provide customers of Acuity Brands — a leading provider of indoor and outdoor LED lighting solutions — with flexible financing options that cover the total cost of upgrading to an energy-efficient LED smart lighting network that may comprise a platform for connecting to the Industrial Internet of Things (IIoT). By doing so, customers can take full advantage of Acuity Brands` LED lighting and controls solutions, which can comprise installation, design and layout, training, commissioning of networked lighting controls, maintenance and other soft costs. Financing with Key Equipment Finance also gives customers the ability to conserve cash and take advantage of the benefits and flexibility of financing capital equipment.
Customers who may want to take advantage of this opportunity comprise those managing qualified municipalities, industrial complexes, educational institutions, healthcare facilities and other businesses that may benefit from financing into one, predictable monthly payment for the complete bundle of services and products from Acuity Brands.
Acuity Brands cited Key Equipment Finance`s 40 years` of industry experience and its longstanding relationship with the company as primary reasons for selecting Key Equipment Finance as its finance partner.
KeyCorp operates as the bank holding company for KeyBank National Association that provides various retail and commercial banking services to individual, corporate, and institutional clients in the United States. The company’s Key Community Bank segment offers deposit and investment products; personal finance services, and loans, counting residential mortgages, home equity, credit cards, and various installment loans for individuals; deposits, investment and credit products, and business advisory services to small businesses; and financial, estate and retirement planning, and asset administration services to high-net-worth clients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
